Age, Lifestyle, Muscle Mechanisms in Insulin Resistance

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-06-30

Study Completion Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the mechanisms by which physical inactivity and obesity alter skeletal muscle insulin signaling to cause insulin resistance and increase the development of impaired glucose tolerance (IGT).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Metformin on Muscle Health of Older Adults

NCT03107884

Muscle Atrophy Insulin Resistance

ACTIVE_NOT_RECRUITING EARLY_PHASE1

Effect of Dietary Glycemic Index on Beta-cell Function

NCT01386645

Impaired Glucose Tolerance Oxidative Stress Prediabetes +1 more

COMPLETED NA

Lifestyle Intervention for Improving Insulin Resistance and Concern for Health

NCT05649176

Insulin Sensitivity Apathy

COMPLETED NA

Microvascular Dysfunction and the Development of Whole-body Insulin Resistance

NCT02628301

Insulin Resistance Type 2 Diabetes Obesity

COMPLETED NA

Exercise-stimulated Muscle Glucose Uptake in Upper Body Obesity

NCT04532814

Upper Body Obesity

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aging is associated with a progressive development of impaired glucose tolerance (IGT), due to an increased peripheral tissue resistance to the action of insulin. Insulin resistance, a common state in both obese and sedentary individuals, eventually leads to the development of glucose intolerance, and type 2 diabetes with aging. Even in the absence of diabetes, insulin resistance is a key feature in various metabolic abnormalities that increase the risk for developing cardiovascular disease (CVD). Previous studies demonstrate improvements in glucose tolerance and glucose utilization following moderate energy restriction coupled with moderate intensity AEX. WL, through behavioral modification of diet and aerobic exercise (AEX), is perhaps the most effective way to treat as well as prevent insulin resistance and its associated metabolic complications of IGT and type 2 diabetes. Although these studies demonstrate the beneficial effect of weight loss (WL) and AEX on glucose tolerance and insulin action, not much is known about the cellular and molecular mechanisms by which these nonpharmacologic treatments improve glucose utilization in high-risk obese older individuals.

This study seeks to determine the cellular mechanisms by which aerobic exercise and weight loss alter skeletal muscle insulin signaling to improve insulin action in older glucose intolerant individuals. A second purpose is to determine whether certain genes (hereditary information) affect the way the body utilizes glucose in response to exercise and weight loss. In addition, adipose tissue is increasingly recognized as more than an inert depot serving not only to accept and store excess energy in the form of triglycerides, but also to secrete hormones and adipokines that have substantial effects on lipid and glucose metabolism. Furthermore, there are depot differences in metabolic function, as well as adipokine content. However, the physiology both underlying and consequential to these observations remains unknown. Thus, a third aim is to examine the effects of obesity on regional adipokine secretion and expression, and the relationship of adipokines to insulin resistance and the metabolic syndrome.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Glucose Intolerance Exercise Capacity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

WL+AEX

Weight loss plus aerobic exercise

Group Type EXPERIMENTAL

Dietary counseling

Intervention Type BEHAVIORAL

1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of \~0.2-0.4 kg/wk

AEX

Intervention Type BEHAVIORAL

Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dietary counseling

1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of \~0.2-0.4 kg/wk

Intervention Type BEHAVIORAL

AEX

Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men older than 50 yrs of age
* Non-smoking (more than 5 years)
* BMI greater than 25 kg/m2 and less than 50 kg/m2

Exclusion Criteria

* CAD, CHF, Myocardial infarction within 6 months or other symptomatic heart disease
* History of stroke, peripheral arterial disease
* Currently being treated for active cancer
* On oral agents or insulin therapy for diabetes
* Poorly controlled Dyslipidemia (abnormal concentration of lipids or lipoproteins in the blood)
* Poorly controlled hypertension (BP \> 180/95)
* Other systematic disorders that are not medically treated and stable
* Physical impairment limiting normal activity and other contraindications to exercise
* Aerobically conditioned
* Abnormal response to exercise (chest pain, significant arrhythmias, extreme shortness of breath, cyanosis, exercising BP \> 240/120)
* Taking warfarin/coumadin
* Taking oral steroids
* Abnormal renal function or liver function
* Chronic pulmonary disease severe enough to require oxygen
* Anemia
* MMSE \< 24, dementia

Minimum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes